Vial

FEBRUARY 29, 2024

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. That is, how many clinical trials are actually managed by these organizations?

Clinical Trials 52

Clinical Trials Trials Clinical Research Marketing 52

Drug Discovery World

SEPTEMBER 6, 2024

Vincent Carrère, CEO of NH TherAguix, added: “This first positive step paves the way for the major next inflexion point expected in the second half of the year regarding the interim efficacy analysis of AGuIX.

Trials 130

Trials Clinical Trials Clinical Development Hospitals 130

Drug Discovery World

JULY 12, 2024

AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of Parkinson’s disease.

Therapies 147

Therapies Clinical Trials FDA Clinical Development 147

Advarra

AUGUST 14, 2023

The clinical research industry is only becoming more complex and competitive as organizations are inundated with multiple trials and tight deadlines. The clinical trial process is both expensive and time-consuming, and ends more often in failure than success. of respondents reported they know what clinical trials are.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. This latest development follows the US Food and Drug Administration (FDA) giving clearance for QN-302 in July 2023 to proceed to this initial clinical trial stage.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

Drug Discovery World

DECEMBER 5, 2023

Cancer Research UK (CRUK), Cancer Research Horizons, and precision oncology company Guardant Health have launched a collaboration to advance cancer treatment. This includes the DETERMINE trial – the first UK national precision medicine trial in rare cancers, and other CRUK and Cancer Research Horizons research collaborations.

Clinical Trials 286

Clinical Trials Drugs Trials Clinical Development 286

Drug Discovery World

DECEMBER 4, 2023

Looking ahead, we are committed to advancing QN-01 into the next stage of clinical development and will be working closely with FDA and MHRA to bring this treatment option to the millions of smokers who want to quit.”

Therapies 130

Therapies Treatment Pharmacokinetics Clinical Development 130

Drug Discovery World

JUNE 6, 2024

months after initial treatment. The global Phase III clinical trial is being led by University College London Hospitals NHS Foundation Trust in the UK and will include around 1,100 people. Ultimately it will contribute to survival rates improving continually over the next decades and more.” It showed that the 2.5-year

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

MAY 23, 2024

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. This study is anticipated to read out in 2H of 2026.

Clinical Trials 130

Clinical Trials Trials Clinical Development Treatment 130

Drug Discovery World

JANUARY 22, 2024

The report reveals a robust sector with significant investment, the highest number of clinical trials in Europe, and NHS patients benefitting from these life-changing treatments. The CGT Catapult database indicates that the UK has remained stable in the number of CGT clinical trials in 2023, despite a global decline of 10%.

Therapies 130

Therapies Clinical Trials Trials Clinical Development 130

Drug Discovery World

FEBRUARY 27, 2024

The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. VXX-401 is currently in a Phase I clinical trial for safety and tolerability, with topline data expected in mid-2024.

Vaccine 260

Vaccine Clinical Trials Disease Clinical Development 260

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. This latest development follows the US Food and Drug Administration (FDA) giving clearance for QN-302 in July 2023 to proceed to this initial clinical trial stage.

Clinical Trials 40

Clinical Trials Treatment Trials Small Molecule 40

Drug Discovery World

NOVEMBER 30, 2023

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation for FT011 for the treatment of systemic sclerosis (scleroderma).

Drug Trials 147

Drug Trials Trials Clinical Trials Drugs 147

Drug Discovery World

FEBRUARY 10, 2023

There were two significant UK regulatory approvals based on key Phase III trial data, while an unusual ‘non-interventional’ study into geographic atrophy enrolled its first patient. The company’s global analysis of all clinical trials conducted in 2022 showed that Covid-19 came second.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Discovery World

DECEMBER 13, 2023

The exploration of FR104/VEL-101’s safety profile seems promising and encourages moving to a Phase II trial.” A Phase II clinical trial of FR104/VEL-101 in patients undergoing kidney transplantation is under preparation by OSE’s partner Veloxis Pharmaceuticals.

Clinical Trials 130

Clinical Trials Hospitals Trials Clinical Development 130

Drug Discovery World

AUGUST 21, 2024

TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer, colorectal cancer, cervical cancer, oesophageal cancer, head and neck cancer, bladder cancer and certain gastrointestinal cancers, but its expression is limited in normal tissues.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Discovery World

APRIL 12, 2024

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. This latest approval means that Enhertu now has five approved indications, including for breast cancer.

Clinical Trials 130

Clinical Trials Trials Engineering FDA 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

MARCH 13, 2023

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.

Trials 130

Trials Clinical Trials Laboratories Clinical Development 130

Drug Discovery World

JULY 5, 2024

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. Targeted, minimally-invasive delivery AVB-101 is delivered as a one-time-only treatment using a minimally invasive, stereotactic neurosurgical procedure directly to the thalamus.

Therapies 147

Therapies Trials Clinical Trials Clinical Development 147

Drug Discovery World

MARCH 18, 2024

Targeted oral peptide JNJ-2113 maintained skin clearance in moderate-to-severe plaque psoriasis (PsO) through one year in the Phase 2b FRONTIER 2 clinical trial extension, Johnson & Johnson (J&J) has reported. JNJ-2113 is the first and only investigational targeted oral peptide designed to block the IL-23 receptor.

Clinical Trials 130

Clinical Trials Drugs Trials Clinical Development 130

Drug Discovery World

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). The post Scleroderma drug gets fast-tracked in the US appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Drugs Therapies Treatment 130

Drug Target Review

OCTOBER 11, 2023

More than 7,000 rare diseases – conditions that affect fewer than 1 in 2,000 people – have been identified, and1 in 17 people will develop a rare disease in their lifetime, with children disproportionately affected. Most of these conditions are genetic in origin and the majority have no effective treatment.

Disease 113

Disease Treatment Small Molecule Therapies 113

Drug Discovery World

MARCH 7, 2024

A combined pipeline of therapeutic candidates Akari’s nomacopan is a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4) being evaluated in a Phase III clinical trial for paediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

Clinical Trials 147

Clinical Trials Licensing Licensing Clinical Development 147

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+

Clinical Research 130

Clinical Research Research Clinical Trials Trials 130

Drug Discovery World

MAY 15, 2023

The US Food and Drug Administration (FDA) has given the go-ahead to CytoAgents to initiate a US Phase Ib/IIa clinical trial investigating CTO1681 for cytokine release syndrome (CRS) in lymphoma patients receiving CAR-T cell therapy. CytoAgents anticipates the clinical trial to launch at its first trial site in the summer of 2023.

FDA Approval 130

FDA Approval FDA Clinical Trials Therapies 130

Drug Discovery World

NOVEMBER 10, 2023

Topline results from a Phase I/II clinical trial have shown that Kiora’s light-restoring small molecule KIO-301 has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP). There was a mean improvement in visual acuity of 0.30

Clinical Trials 130

Clinical Trials Small Molecule Trials Clinical Development 130

Drug Discovery World

JANUARY 25, 2024

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy.

FDA 130

FDA Drugs Clinical Trials Clinical Development 130

Drug Discovery World

MARCH 13, 2024

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. Across JNJ-2113 treatment groups, 58.6% at 16 weeks and 76.2% at 52 weeks).

Trials 130

Trials Clinical Trials Treatment Licensing 130

Drug Discovery World

NOVEMBER 23, 2023

Minoryx has announced enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in the US Phase III clinical trial, CALYX. This will push the Phase III CALYX trial forward and bring leriglitazone to patients as quickly as possible,” said Sílvia Pascual, VP Clinical Development, Minoryx. “In

Trials 130

Trials Clinical Trials FDA Approval FDA 130

Drug Discovery World

DECEMBER 8, 2023

“The future development of this combination therapy alongside our monotherapy clinical trials will help expand patient options and narrow the gap towards improving the long-term survival of patients with hepatocellular carcinoma.” Both companies will share the costs of manufacturing and preclinical assessments.

Therapies 130

Therapies Clinical Trials Engineering Clinical Development 130

Drug Discovery World

AUGUST 22, 2023

Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001 , a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS). BL-001 shows promise as a novel treatment option that can change lives.

Trials 130

Trials Clinical Trials Science Clinical Development 130

The Pharma Data

DECEMBER 14, 2020

The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. CIPN is a leading cause for modification or interruption of chemotherapy.

Clinical Development 52

Clinical Development Clinical Supply Pharmacokinetics Packaging 52

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We

Research 130

Research Clinical Trials Therapies Clinical Development 130

Drug Discovery World

FEBRUARY 12, 2024

We’re already seeing biotechs making breakthroughs with AI in this area, with more than 150 small molecule drugs discovered and 15 already in clinical trials. Kishen Chahwala, PhD, Business Development Manager, Enhanc3D Genomics “AI is transforming the way we fight cancer by unlocking the secrets of large and complex datasets.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

MAY 29, 2024

Biomica has revealed encouraging initial findings from an ongoing Phase I clinical trial of its microbiome-based immuno-oncology candidate, BMC128, in combination with an anti-PD1 immune checkpoint inhibitor. The trial is assessing the drug in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC).

Trials 130

Trials Clinical Trials Treatment Clinical Development 130

Drug Discovery World

FEBRUARY 28, 2024

According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. The drug, MOv18 IgE (an anti-folate receptor alpha IgE antibody), was developed by researchers at King’s College London. expressing cancers.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162